RU2012134351A - Способы лечения дисфункции мейбомиевых желез - Google Patents

Способы лечения дисфункции мейбомиевых желез Download PDF

Info

Publication number
RU2012134351A
RU2012134351A RU2012134351/15A RU2012134351A RU2012134351A RU 2012134351 A RU2012134351 A RU 2012134351A RU 2012134351/15 A RU2012134351/15 A RU 2012134351/15A RU 2012134351 A RU2012134351 A RU 2012134351A RU 2012134351 A RU2012134351 A RU 2012134351A
Authority
RU
Russia
Prior art keywords
meibomian glands
halogen atom
secretion
reduced
nhcor
Prior art date
Application number
RU2012134351/15A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс Т. Далтон
Джитендра ЭСВАРАКА
Original Assignee
ДЖиТиЭкс, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ДЖиТиЭкс, ИНК. filed Critical ДЖиТиЭкс, ИНК.
Publication of RU2012134351A publication Critical patent/RU2012134351A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RU2012134351/15A 2010-01-11 2011-01-11 Способы лечения дисфункции мейбомиевых желез RU2012134351A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29396610P 2010-01-11 2010-01-11
US61/293,966 2010-01-11
PCT/US2011/020871 WO2011085385A1 (en) 2010-01-11 2011-01-11 Methods of treating meibomian gland dysfunction

Publications (1)

Publication Number Publication Date
RU2012134351A true RU2012134351A (ru) 2014-02-20

Family

ID=44259000

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012134351/15A RU2012134351A (ru) 2010-01-11 2011-01-11 Способы лечения дисфункции мейбомиевых желез

Country Status (10)

Country Link
US (1) US8791158B2 (https=)
EP (1) EP2523556A4 (https=)
JP (1) JP2013516501A (https=)
KR (1) KR20120115380A (https=)
CN (1) CN103002737A (https=)
AU (1) AU2011203832A1 (https=)
CA (1) CA2787114A1 (https=)
MX (1) MX2012008110A (https=)
RU (1) RU2012134351A (https=)
WO (1) WO2011085385A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
US9381183B2 (en) * 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US10064818B2 (en) * 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
RU2567829C1 (ru) * 2014-10-22 2015-11-10 Елизавета Геннадьевна Полунина Способ оценки морфофункционального состояния мейбомиевых желез - биометрия мейбомиевых желез
KR101714710B1 (ko) 2015-09-17 2017-03-10 고려대학교 산학협력단 마이봄샘 압출기
CN114469991A (zh) 2016-04-14 2022-05-13 阿祖拉眼科有限公司 用于治疗睑板腺功能障碍的二硫化硒组合物
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US20230168157A1 (en) * 2021-11-29 2023-06-01 Petróleo Brasileiro S.A. - Petrobras System and method for evaluation of the deposition in tubes of the furnaces of a delayed coking unit
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US20050038110A1 (en) * 2000-08-24 2005-02-17 Steiner Mitchell S. Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) * 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US8445534B2 (en) * 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7919647B2 (en) * 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7253210B2 (en) 2002-10-15 2007-08-07 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20070173546A1 (en) * 2000-08-24 2007-07-26 Dalton James T Selective androgen receptor modulators and method of use thereof
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) * 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
IL154425A0 (en) * 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
EP1325914A4 (en) * 2000-09-14 2004-11-17 Kaken Pharma Co Ltd TETRAHYDROQUINOLINE COMPOUNDS
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
CA2476657A1 (en) * 2002-02-28 2003-09-12 The University Of Tennessee Research Corporation Haloacetamide and azide substituted compounds and methods of use thereof
EP1487458B1 (en) * 2002-02-28 2011-11-16 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7772433B2 (en) * 2002-02-28 2010-08-10 University Of Tennessee Research Foundation SARMS and method of use thereof
GEP20074209B (en) 2002-02-28 2007-10-10 , Multi-substitued selective androgen receptor modulators and methods of use thereof
GEP20074191B (en) * 2002-06-17 2007-09-10 Univ Tennessee Res Foundation N-bridged selective androgen receptor modulators and methods of use thereof
US20040197928A1 (en) * 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
JP2006518328A (ja) * 2002-10-15 2006-08-10 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 複素環選択的アンドロゲン受容体調節剤及びその使用方法
US20040265916A1 (en) * 2002-10-15 2004-12-30 Dalton James T. Method for detecting selective androgen receptor modulators
AU2003287075A1 (en) * 2002-10-15 2004-05-04 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
WO2004035739A2 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2457892A1 (en) * 2003-01-13 2012-05-30 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
JP2006516286A (ja) 2003-01-22 2006-06-29 ジーティーエックス・インコーポレイテッド Ｓａｒｍによる女性のアンドロゲン減少に関連する病気の治療
CA2522874A1 (en) * 2003-12-16 2005-07-07 Gtx, Inc. Prodrugs of selective androgen receptor modulators and methods of use thereof
US20070082017A1 (en) * 2004-01-10 2007-04-12 Tseng Scheffer C Lipid compositions and methods of use
US20110237664A1 (en) 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
US20130034562A1 (en) * 2004-06-07 2013-02-07 Dalton James T Selective androgen receptor modulators for treating diabetes
ATE552235T1 (de) 2004-06-07 2012-04-15 Univ Tennessee Res Foundation Selektive androgen-rezeptor-modulator und anwendungsverfahren dafür
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
JP4899625B2 (ja) * 2006-05-12 2012-03-21 スズキ株式会社 鞍乗型不整地走行車両
PT2038252T (pt) * 2006-07-12 2016-12-16 Univ Tennessee Res Found Acilanilidos substituidos e métodos de utilização dos mesmos
CA2658098A1 (en) * 2006-07-19 2008-01-24 Osurf Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CN101528214B (zh) * 2006-08-24 2013-06-05 田纳西大学研究基金会 取代的n-酰基苯胺及其使用方法
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
HRP20180500T1 (hr) * 2007-09-11 2018-06-01 Gtx, Inc. Kristalni polimorf selektivnih modulatora androgena (r) ili (s)-n-(4-cijano-3-(trifluorometil)fenil)-3-(4-cijanofenoksi)-2-hidroksi-2-metilpropanamida
US7968603B2 (en) * 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication

Also Published As

Publication number Publication date
CA2787114A1 (en) 2011-07-14
US8791158B2 (en) 2014-07-29
JP2013516501A (ja) 2013-05-13
MX2012008110A (es) 2012-10-03
KR20120115380A (ko) 2012-10-17
US20110172302A1 (en) 2011-07-14
EP2523556A1 (en) 2012-11-21
CN103002737A (zh) 2013-03-27
WO2011085385A1 (en) 2011-07-14
AU2011203832A1 (en) 2012-08-23
EP2523556A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
RU2012134351A (ru) Способы лечения дисфункции мейбомиевых желез
JP2013516501A5 (https=)
AU712927B2 (en) Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics
US20260027079A1 (en) Cannabinoid acid ester compositions and uses thereof
RU2017112308A (ru) Композиции и способы для лечения бессонницы
ITFI20100113A1 (it) Spray nasale liquido contenente naltrexone a bassi dosaggi.
EP2854779A1 (en) Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112015026332A2 (pt) composição farmacêutica oral para a prevenção ou para o tratamento da síndrome do olho seco compreendendo rebamipida ou um profármaco da mesma
RU2017115726A (ru) Ингибиторы лизин-специфичного гингипаина
EA201300314A8 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP6749962B2 (ja) 網脈絡膜障害の抑制剤
ES2324130B1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes reductores de la hipertension ocular.
JP2016175900A (ja) 徐放性医薬組成物
RU2690490C2 (ru) Способ стабилизации дибутилгидрокситолуола
JPWO2018203424A1 (ja) 点眼剤
WO2006049250A1 (ja) 眼内移行性促進水性点眼剤
CN105596336B (zh) 化合物sr8278在制备治疗i型糖尿病角膜病变药物中的应用
TW201038297A (en) Narcotic emulsion formulations for treatment of cancer pain
CN105566100A (zh) 一种苯乙烯酸类化合物，包含其的组合物及其应用
US3374144A (en) Ophthalmic composition
RU2013148799A (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
ES2717481T3 (es) Engrosamiento corneal central reducido mediante el uso de profármacos de ésteres hidrófilos de beta-clorociclopentanos
TWI713618B (zh) 外用劑
WO2019067974A1 (en) ANTI-INFLAMMATORY, ANTICANCER AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING AND USING THEM
CN106974916A (zh) 奥贝胆酸和二甲双胍的复方组合物及其应用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20150803